Skip to Content

'
Michael W. Bevers, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Michael W. Bevers, Professor in the Department of Gynecologic Oncology and Director of the Gynecologic Oncology Outreach Program since 2008, has been named the September 2006 Educator of the Month.  Since arriving at M.D. Anderson in 1994, Dr. Bevers has been instrumental in both education of young physicians and treatment of gynecologic cancers at several institutions in the Houston area.  Specifically, he has been an instructor for two Professional Education for Prevention and Early Detection courses, a Department of Surgical Oncology course, and a Medical Oncology Review Course on topics related to gynecologic oncology at M.D. Anderson; a course on surgical complications in the Departments of Obstetrics and Gynecology at The University of Texas Health Science Center at Houston; a course on endometrial cancer at Baylor College of Medicine; and a course on pelvic surgery and anatomy at The University of Texas Medical School at Houston.  In addition, Dr. Bevers led a Novartis Preceptorship Lecture Series on treatment of ovarian cancer at M.D. Anderson in 2000 and was a Co-Chairman of the Early Detection of Women's Cancers - Partnering with the Women's Health Community meeting at M.D. Anderson in 2005.  On the treatment side, Dr. Bevers has been a prime mover in providing gynecologic oncology services in Houston as Director of the Gynecologic Oncology Outreach Program.  This program, which began with the establishment of outreach relationships between M.D. Anderson and six other hospitals in the community, greatly expanding the diagnostic and treatment options for patients with gynecologic cancers.  Dr. Bevers was honored for his educational work with the Association of Professors of Gynecologiy and Obstetrics Excellence in Teaching Award and in 2003 with the M.D. Anderson Outstanding Educator Award and the Baylor College of Medicine Gynecologic Exceptional Teaching Award.  Furthermore, he has been on the Best Doctors in America list every year since 2003, was named to the America's Top Obstetricians and Gynecologists list in 2004, and was named a Texas Super-Doc from 2004 to 2008.

Dr. Bevers received his M.D. degree from The University of Texas Health Science Center at San Antonio in 1990.  After completing an internship in 1991 and residency in Obstetrics and Gynecology in 1994 at Parkland Memorial Hospital at The University of Texas Southwestern Medical School at Dallas, Dr. Bevers came to M.D. Anderson as a Fellow in Gynecologic Oncology and a Junior Faculty Associate in the Department of Gynecologic Oncology.  In 1996, Dr. Bevers was promoted to Assistant Professor of Gynecologic Oncology and named Director of Gynecologic Oncology Medical Information Systems and Coordinator of the St. Luke's Gynecologic Oncology Outreach Pilot.  After being named Director of the Gynecologic Oncology Outreach Program in 2001, Dr. Bevers was promoted to Associate Professor in the Department of Gynecologic Oncology in 2002.  Dr. Bevers has been a member of the M.D. Anderson Fellowship Planning Committee since 2003 and the M.D. Anderson Surgery Working Group since 2005.  He is also a member of the active, provisional, or consulting staff of seven local hospitals.  In addition to his numerous clinical and educational duties, Dr. Bevers has served on the Government Affairs Committee of the Society of Clinical Gynecologists since 1997 and as Editor of the Handbook of Gynecologic Oncology since 1999.  During his time at M.D. Anderson, Dr. Bevers has written numerous articles published in refereed journals, abstracts, and book chapters on an array of topics pertaining to gynecologic cancer.

Office Address

The University of Texas MD Anderson Cancer Center
Regional Care Center Katy
19770 Kingsland Blvd
Unit Number: 2052
Houston, TX 77094
Phone: 713-563-9600
Fax: 281-646-4320

Education & Training

Degree-Granting Education

1990 The University of Texas Health Science Center, San Antonio, TX, MD, Medicine
1985 Texas Wesleyan University, Fort Worth, TX, BS, Biology

Postgraduate Training

7/1994-6/1996 Clinical Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Hospital Cancer Center, Houston, TX, Dr. Mitchell Morris
7/1991-6/1994 Clinical Residency, Obstetrics and Gynecology, The University of Texas Southwestern Medical School, Dallas, TX, Dr. Alvin Brekken
7/1990-6/1991 Clinical Internship, The University of Texas Southwestern Medical School, Dallas, TX, Dr. Alvin Brekken

Honors and Awards

2006 APGO Exellence in Teaching Award
2004-2012 Educator of the Month, October, The University of Texas M.D. Anderson Cancer Center
2004-2011 Texas Super-Doc
2004 Americas Top Obstetricians and Gynecologists
2003-2012 Best Doctors in America
2003 Gynecologic Exceptional Teaching Award, Baylor College of Medicine
2003 Outstanding Educator, The University of Texas M.D. Anderson Cancer Center
1994 Outstanding Resident Teaching Award, The University of Texas Southwestern Medical School, Parkland Memorial Hospital
1994 Texas Residents Research Symposium Award for Best Resident Research Project, The University of Texas Southwestern Medical School, Parkland Memorial Hospital

Professional Memberships

American College of Obstetrics and Gynecologists
Member, 1998-present
American Society of Clinical Oncologists
Member, 2001-present
Felix Rutledge Society
Member, 1996-present
Harris County Medical Society
Member, 1994-present
Houston Gynecological & Obstetrical Society
Member, 1996-present
M.D. Anderson Associates
Member, 1994-present
Society of Gynecologic Oncologists
Member, 2001-present
Texas Association of Obstetrics and Gynecologists
Member, 1996-present
Texas Medical Association
Member, 1994-present
Texas Medical Foundation
Member, 1994-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Jones KL, Saucier JM, Sun CC, Bevers MW, Ramondetta LM, Brown J, Smith JA. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract 14(1):31-6, 2008 March, 3/2008.
2. Ramirez PT, Frumovitz M, Dos Reis R, Milam MR, Bevers MW, Levenback CF, Coleman RL. Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer 18(3):571-5, 2008 May-June, 2008.
3. Frumovitz M, Dos Reis R, Sun CC, Milam MR, Bevers MW, Brown J, Slomvitz BM, Ramirez PT. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol 110(1):96-102, 2007.
4. Said HK, Bevers M, Butler CE. Reconstruction of the pelvic floor and perineum with human acellular dermal matrix and thigh flaps following pelvic exenteration. Gynecol Oncol 107(3):578-82, 2007 Dec, 2007.
5. Slomovitz BM, Ramirez PT, Frumovitz M, Soliman PT, Bevers M, Coleman RL, Levenback C. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol 102:534-6, 9/2006. PMID: 16483643.
6. de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med 68(4):555-62, 7/2006. PMID: 16868264.
7. Stevens TA, Brown J, Zander DS, Bevers MW, Gershenson DM, Ramondetta LM. Adult granulosa cell tumors of the ovary in two first-degree relatives. Gynecol Oncol 98(3):502-5, 9/2005. PMID: 15992917.
8. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-27, 4/2005. PMID: 15538640.
9. Ramirez PT, Sun CC, Vidal CI, Schimp V, Slomovitz BM, Bevers MW, Bodurka DC. Outcomes of hysteroscopy and hysterectomy in breast cancer patients. Cancer Ther 3:147-152, 2005.
10. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-24, 6/2004. PMID: 15122311.
11. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Frozen section analyses as predictors of lymphatic spread in patients with early stage uterine cancer. J Amer Coll Surg 199:388-393, 2004.
12. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 90(3):529-36, 9/2003. PMID: 13678720.
13. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, Wolf JK. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 85(2):285-91, 5/2002. PMID: 11972389.
14. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Jr, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-6, 9/2001. PMID: 11520135.
15. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 7/2001. PMID: 11454891.
16. Levenback C, Coleman R, Burke TW, Bevers M, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 83(2):276-281, 2001.
17. Ramondetta L, Burke TW, Levenback C, Bevers MW, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 82(1):156-161, 2001.
18. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, Wharton JT. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78(2):187-93, 8/2000. PMID: 10926801.
19. Parker LP, Parker JR, Bodurka-Bevers D, Deavers M, Bevers MW, Shen-Gunther J, Gershenson DM. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol 77(1):183-9, 4/2000. PMID: 10739709.
20. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-1140, 2000.
21. Verschraegen CF, Levenback C, Vincent M, Wolf J, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ. Phase II study of intravenous Dx-891f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Ann N Y Acad Sci 922:349-351, 2000.
22. Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anti-Cancer Drugs 11(7):565-568, 2000.
23. Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. The current status of surgical staging of ovarian serous borderline tumors. Cancer 85(4):905-11, 2/1999. PMID: 10091769.

Last updated: 8/28/2013